Wall Street analysts expect Esperion Therapeutics Inc (NASDAQ:ESPR) to announce earnings per share (EPS) of ($2.71) for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Esperion Therapeutics’ earnings, with the lowest EPS estimate coming in at ($2.80) and the highest estimate coming in at ($2.61). Esperion Therapeutics reported earnings per share of ($2.24) during the same quarter last year, which suggests a negative year-over-year growth rate of 21%. The business is expected to issue its next quarterly earnings results on Thursday, February 27th.
According to Zacks, analysts expect that Esperion Therapeutics will report full-year earnings of ($4.03) per share for the current fiscal year, with EPS estimates ranging from ($4.25) to ($3.88). For the next fiscal year, analysts forecast that the firm will report earnings of ($6.35) per share, with EPS estimates ranging from ($10.05) to ($3.55). Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that follow Esperion Therapeutics.
Esperion Therapeutics (NASDAQ:ESPR) last released its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($2.37) EPS for the quarter, missing analysts’ consensus estimates of ($1.95) by ($0.42). The company had revenue of $0.98 million during the quarter, compared to analyst estimates of $0.99 million. During the same period in the prior year, the firm earned ($1.86) earnings per share.
In other news, major shareholder Target N. V. Biotech acquired 80,000 shares of the business’s stock in a transaction dated Wednesday, September 4th. The shares were purchased at an average price of $33.78 per share, with a total value of $2,702,400.00. Following the transaction, the insider now directly owns 3,652,964 shares in the company, valued at $123,397,123.92. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Timothy M. Mayleben acquired 2,500 shares of Esperion Therapeutics stock in a transaction that occurred on Friday, September 6th. The shares were purchased at an average price of $35.25 per share, with a total value of $88,125.00. Following the purchase, the chief executive officer now owns 76,015 shares in the company, valued at $2,679,528.75. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 167,500 shares of company stock worth $5,943,925. Insiders own 7.70% of the company’s stock.
A number of large investors have recently made changes to their positions in ESPR. Vanguard Group Inc. grew its stake in shares of Esperion Therapeutics by 27.9% during the second quarter. Vanguard Group Inc. now owns 2,247,286 shares of the biopharmaceutical company’s stock worth $104,543,000 after acquiring an additional 489,863 shares during the last quarter. BlackRock Inc. boosted its stake in Esperion Therapeutics by 6.8% in the 2nd quarter. BlackRock Inc. now owns 1,983,420 shares of the biopharmaceutical company’s stock worth $92,270,000 after purchasing an additional 125,747 shares in the last quarter. Rhenman & Partners Asset Management AB grew its position in Esperion Therapeutics by 59.2% during the 3rd quarter. Rhenman & Partners Asset Management AB now owns 655,854 shares of the biopharmaceutical company’s stock worth $24,044,000 after purchasing an additional 243,761 shares during the last quarter. Nuveen Asset Management LLC purchased a new stake in Esperion Therapeutics during the 2nd quarter worth approximately $17,898,000. Finally, Northern Trust Corp increased its stake in Esperion Therapeutics by 0.9% during the 2nd quarter. Northern Trust Corp now owns 292,722 shares of the biopharmaceutical company’s stock valued at $13,617,000 after purchasing an additional 2,689 shares in the last quarter.
NASDAQ ESPR traded down $0.87 during trading on Friday, hitting $44.78. The stock had a trading volume of 31,055 shares, compared to its average volume of 361,291. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.41 and a current ratio of 4.41. The stock has a market capitalization of $1.11 billion, a price-to-earnings ratio of -5.94 and a beta of 1.86. Esperion Therapeutics has a one year low of $33.13 and a one year high of $58.50. The stock has a 50 day simple moving average of $39.26 and a 200 day simple moving average of $42.46.
Esperion Therapeutics Company Profile
Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.
Further Reading: Convertible Shares
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.